Heart failure & cardiomyopathies
Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir: A Pilot PET/CT Study
Authors' conclusion
124I-evuzamitide demonstrates uptake by cardiac amyloid and accurately discriminates amyloid CMP from control subjects. In AL-CMP, discrimination performance is similar to 18F-florbetapir. In ATTRwt-CMP, performance may be better with 124I-evuzamitide.
Study context
- Population
- Participants with amyloid cardiomyopathy and control subjects
- Participants
- 46 participants
- Comparison
- 124I-evuzamitide vs 18F-florbetapir PET/CT
- AL-CMPn = 12
- ATTRwt-CMPn = 12
- Hereditary amyloidosisn = 2
- Controln = 20reference
- Outcome
- Myocardial 124I-evuzamitide uptake (LV %ID) and its diagnostic value vs 18F-florbetapir
Methodological detailspilot study
- Pilot study
Performance
As reported in the abstract
124I-evuzamitide LV %ID
AL-CMP
1.48
median · IQR 1.12–1.89
ATTRwt-CMP
2.12
median · IQR 1.66–2.47
Control
0.00
median · IQR 0.00–0.01
- Differed across groups
- overall P < 0.001
Further findings
LV %ID, 124I-evuzamitide vs 18F-florbetapir, ATTRwt-CMP
- Higher with 124I-evuzamitide than 18F-florbetapir
- P = 0.002
Correlation of 124I-evuzamitide LV %ID with echocardiography and CMR metrics
- Interventricular septum thickness (Spearman's ρ)
- 0.78
- LV global longitudinal strain (ρ)
- 0.54
- LV mass index (ρ)
- 0.82
- Extracellular volume (ρ)
- 0.51
Original publication
Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir: A Pilot PET/CT Study. JACC Cardiovasc Imaging. Published 6 September 2023. doi:10.
Summarised from the published abstract; every number is checked against it